Co-innovation programme between Enterprise Singapore and Charite/BIH In November 2023, the signing of a Memorandum of Understanding (MoU) between Charité - Universitätsmedizin Berlin, the Berlin Institute of Health (BIH) and Enterprise Singapore for a co-innovation program laid the foundation for a professional network of start-ups from Singapore…
Workshop "Serious Transfer Game @BIH-Charité: Play your way through the options of technology transfer" Your research results are relevant for practical application, but the numerous options open to you in technology transfer are confusing - where should you start? What should you do? In this interactive and innovative serious game, you as a group…
Program and call for proposals The aim of the current call (start 01.03.2024) at Enterprise Singapore is to shape our partnership through transnational project work. New technologies and medical innovations from Singapore companies are to be further developed together with Charité and BIH researchers so that they can be made available to patients…
Background In November 2023, a Memorandum of Understanding was signed between Charité-Universitätsmedizin Berlin, the Berlin Institute of Health Sciences and Enterprise Singapore, the Singapore government agency championing enterprise development, with the aim of strengthening international collaboration and translational research. Building on this…
Agenda Table Process stage Deadline Publication of the call 01.03.2024 Startups submit Expression of Interest (EoI) to Enterprise Singapore April 2024 First phase: Startups and Charité/BIH employees are "matched", (Letter of Intent, LoI from Charité/BIH employees), shortlist of selected startups for second phase is submitted to ES May 2024 Second…
Startups The short profiles of the startups can be found here: Short profiles Acumen Diagnostics Medical field: Infectious diseases Product type: Medical devices, diagnostics and therapeutics Growth stage: Development Team: 30 people Description of product: Unyvero A30 SHR (Sepsis Host Response) is a blood-based, host response gene expression test,…
Call for proposals The aim of the current call for proposals (start September 19,2022) at the Israel Innovation Authority (IIA) is the concrete development of a partnership on the basis of transnational project work. New technologies and medical innovations from Israeli companies are to be further developed together with Charité and BIH researchers…
Israeli innovations at Charité and BIH In September 2019, the Israel Innovation Authority (IIA) and Charité-Universitätsmedizin Berlin and the BIH signed a Memorandum of Understanding (MoU) to cooperate in the field of technological innovation in healthcare and invite interested companies to submit applications to validate and test as well as adapt…
Background The Israel Innovation Authority (IIA) supports international collaborations of Israeli startups with partners from science and research worldwide. In September 2019, a Memorandum of Understanding was signed between Charité-Universitätsmedizin Berlin, the Berlin Institute of Health and the IIA, with the aim of strengthening international…
Agenda Agenda Process step Period Publication of the International Health-Tech Pilot Program 19/09/2022 Application process Startups: submitting expression of interest (EoI) to IIA 14/11/2022 First phase: Startups and Charité/BIH employees are "matched", (Letter of Intent, LoI by Charité/BIH employees), shortlist of selected startups for second…